Brief: Simcere Pharmaceutical Group Posts H1 Revenue Of RMB3,114 Mln
21/08/2024 15:42
Aug 21 (Reuters) - Simcere Pharmaceutical Group H1 basic EPS RMB 0.18. * H1 revenue RMB 3,114 million * H1 net income RMB 457 million
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660